// App-Quantinova.ai

660.0 : Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.

Researchers

Presenter

  • Heinz-Josef Lenz

Principal Investigators

  • Takayuki Yoshino

  • Guillem Argiles

  • Timothy Iveson

  • Javier Sastre

  • Mark Harrison

  • Howard John Lim

  • Niall C. Tebbutt

  • Marc Peeters

  • Taroh Satoh

  • Christian Dittrich

  • Mouna Sassi

  • Arsene-Bienvenu Loembe

  • Eric Van Cutsem

Medical Centers

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • National Cancer Center Hospital, Tokyo, Japan

  • Vall dHebron University Hospital and Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain

  • Southampton General Hospital, Southampton, United Kingdom

  • Mount Vernon Hospital, Northwood, United Kingdom

  • Division of Medical Oncology, BC Cancer Agency, Vancouver Centre, Vancouver, BC, Canada

  • Austin Health, Melbourne, Australia

  • Antwerp University Hospital, Edegem, Belgium

  • Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan

  • ACR-ITR VIEnna and Centre for Oncology and Haematology, Kaiser-Franz-Josef-Spital, Vienna, Austria

  • Boehringer Ingelheim GmbH, Reims, France

  • Boehringer Ingelheim B.V., Alkmaar, Netherlands

Locations

  • United States

  • Japan

  • Spain

  • United Kingdom

  • Canada

  • Australia

  • Belgium

  • Austria

  • France

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Oxaliplatin

  • Regorafenib

  • Irinotecan

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02149108

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved